• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由于缓冲液的非理想性,透析过滤过程中的pH值变化。

pH variations during diafiltration due to buffer nonidealities.

作者信息

Baek Youngbin, Yang Deyu, Singh Nripen, Arunkumar Abhiram, Ghose Sanchayita, Li Zheng Jian, Zydney Andrew L

机构信息

Dept. of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802.

Product Development, Bristol-Myers Squibb, Devens, MA, 01434.

出版信息

Biotechnol Prog. 2017 Nov;33(6):1555-1560. doi: 10.1002/btpr.2544. Epub 2017 Sep 4.

DOI:10.1002/btpr.2544
PMID:28840650
Abstract

Diafiltration is used for final formulation of essentially all biotherapeutics. Several studies have demonstrated that buffer/excipient concentrations in the final diafiltered product can be different than that in the diafiltration buffer due to interactions between buffer species and the protein product. However, recent work in our lab has shown variations in solution pH that are largely independent of the protein concentration during the first few diavolumes. Our hypothesis is that these pH variations are due to nonidealities in the acid-base equilibrium coefficient. A model was developed for the diafiltration process accounting for the ionic strength dependence of the pK . Experimental results obtained using phosphate and histidine buffers were in excellent agreement with model predictions. A decrease in ionic strength leads to an increase in the pK for the phosphate buffer, causing a shift in the solution pH, even under conditions where the initial feed and the diafiltration buffer are at the same pH. This effect could be eliminated by matching the ionic strength of the feed and diafiltration buffer. The experimental data and model provide new insights into the factors controlling the pH profile during diafiltration processes. © 2017 American Institute of Chemical Engineers Biotechnol. Prog., 33:1555-1560, 2017.

摘要

渗滤用于基本上所有生物治疗药物的最终制剂。多项研究表明,由于缓冲液成分与蛋白质产品之间的相互作用,最终渗滤产物中的缓冲液/辅料浓度可能与渗滤缓冲液中的不同。然而,我们实验室最近的工作表明,在最初的几个渗滤体积期间,溶液pH值的变化在很大程度上与蛋白质浓度无关。我们的假设是,这些pH值变化是由于酸碱平衡系数的非理想性。针对渗滤过程开发了一个模型,该模型考虑了pK对离子强度的依赖性。使用磷酸盐和组氨酸缓冲液获得的实验结果与模型预测非常吻合。离子强度的降低会导致磷酸盐缓冲液的pK增加,从而导致溶液pH值发生变化,即使在初始进料和渗滤缓冲液处于相同pH值的条件下也是如此。通过使进料和渗滤缓冲液的离子强度匹配,可以消除这种影响。实验数据和模型为控制渗滤过程中pH值分布的因素提供了新的见解。©2017美国化学工程师学会生物技术进展,33:1555 - 1560,2017。

相似文献

1
pH variations during diafiltration due to buffer nonidealities.由于缓冲液的非理想性,透析过滤过程中的pH值变化。
Biotechnol Prog. 2017 Nov;33(6):1555-1560. doi: 10.1002/btpr.2544. Epub 2017 Sep 4.
2
Mass Balance Model with Donnan Equilibrium Accurately Describes Unusual pH and Excipient Profiles during Diafiltration of Monoclonal Antibodies.采用唐南平衡的质量平衡模型准确描述单克隆抗体在渗滤过程中异常的 pH 值和赋形剂分布。
Biotechnol J. 2019 Jul;14(7):e1800517. doi: 10.1002/biot.201800517. Epub 2019 May 20.
3
Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies.预测单克隆抗体最终超滤/透析步骤的透析液组成。
Biotechnol Bioeng. 2011 Jun;108(6):1338-46. doi: 10.1002/bit.23067. Epub 2011 Feb 19.
4
pH and excipient profiles during formulation of highly concentrated biotherapeutics using bufferless media.在使用无缓冲剂介质的情况下,高浓度生物制剂配方过程中的 pH 值和赋形剂特性。
Biotechnol Bioeng. 2020 Nov;117(11):3390-3399. doi: 10.1002/bit.27502. Epub 2020 Jul 28.
5
Effect of protein and solution properties on the Donnan effect during the ultrafiltration of proteins.蛋白质和溶液性质对蛋白质超滤过程中唐南效应的影响。
Biotechnol Prog. 2011 Jan-Feb;27(1):140-52. doi: 10.1002/btpr.523. Epub 2010 Dec 3.
6
Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody.治疗性抗体最终超滤/渗滤步骤中辅料浓度的理论分析
Biotechnol Prog. 2009 Jul-Aug;25(4):964-72. doi: 10.1002/btpr.168.
7
Hollow fiber countercurrent dialysis for continuous buffer exchange of high-value biotherapeutics.中空纤维对流转运透析用于高价值生物治疗药物的连续缓冲液交换。
Biotechnol Prog. 2019 Mar;35(2):e2763. doi: 10.1002/btpr.2763. Epub 2018 Dec 21.
8
A Small-Scale Process for Predicting Donnan and Volume Exclusion Effects During Ultrafiltration/Diafiltration Process Development.超滤/错流过滤过程开发中预测唐南和体积排除效应的小规模方法。
J Pharm Sci. 2018 May;107(5):1296-1303. doi: 10.1016/j.xphs.2018.01.010. Epub 2018 Jan 12.
9
Buffer solutions in drug formulation and processing: How pK values depend on temperature, pressure and ionic strength.药物制剂和加工中的缓冲溶液:pK 值如何随温度、压力和离子强度而变化。
Int J Pharm. 2019 Apr 5;560:357-364. doi: 10.1016/j.ijpharm.2019.02.019. Epub 2019 Feb 22.
10
A mechanistic model to account for the Donnan and volume exclusion effects in ultrafiltration/diafiltration process of protein formulations.用于解释蛋白质配方超滤/渗滤过程中 Donnan 和体积排除效应的机理模型。
Biotechnol Prog. 2021 Mar;37(2):e3106. doi: 10.1002/btpr.3106. Epub 2020 Dec 14.